The VoluFaTE project addresses a central limitation in tissue engineering and regenerative medicine: the lack of stable and long-term control over cellular function in engineered living tissues. Although significant progress has been achieved through biomaterial design, biochemical stimulation, and spatial structuring, these approaches rely on external microenvironmental cues and assume that cells remain responsive to them. In clinically relevant and diseased in vivo environments, this control is frequently lost, leading to impaired tissue function or implant failure.
Emerging evidence from fundamental cell biology has identified cell volume and intracellular molecular crowding as critical regulators of cellular signaling, transcriptional activity, and fate decisions. Importantly, volumetric changes determine how cells sense and respond to regenerative and degenerative stimuli, independent of continuous biochemical intervention. This insight creates a strategic opportunity to shift tissue engineering paradigms from external microenvironmental control toward intrinsic programming of how cells physically experience their surroundings. However, despite its high potential, no scalable and translatable technology currently exists to impose stable volumetric control on cells within three-dimensional engineered tissues.
The overall objective of VoluFaTE is to develop a first-in-class, non-invasive and scalable platform for volumetric programming of individual cells in 3D environments, building directly on the ability to precisely control cell volume using extracellular osmolarity. Osmotically driven volume control is used as a robust and reversible reference strategy to define functionally relevant volumetric states and their associated molecular crowding profiles. These volume-adjusted cells are subsequently encapsulated within sacrificial single-cell microgels, integrated into modular bio-inks, and released to form defined cell-sized microcavities that maintain long-term cell volume in three dimensions. Cartilage tissue engineering serves as a clinically relevant proof-of-principle, given the direct link between osmolarity, chondrocyte volume, and osteoarthritic degeneration, while the underlying platform is designed for broad applicability across tissues and disease contexts. The project pathway to impact progresses from controlled volumetric programming at the single-cell level to functional tissue formation and in vivo validation. By enabling engineered tissues to maintain regenerative behavior even in diseased environments, VoluFaTE aligns with European strategic priorities in regenerative medicine, reduction of animal experimentation, and advanced biomedical technologies. At midterm, the project remains fully aligned with its original objectives, contributing to the establishment of volumetric programming as a new paradigm for engineering functional living tissues.